Assertio Stock (NASDAQ:ASRT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.97

52W Range

$0.73 - $1.80

50D Avg

$1.10

200D Avg

$1.09

Market Cap

$90.70M

Avg Vol (3M)

$588.76K

Beta

0.83

Div Yield

-

ASRT Company Profile


Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

53

IPO Date

Dec 03, 1997

Website

ASRT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
C A M B I A$24.72M$24.97M$28.35M
Other Revenue$-1.29M$-985.00K-
Zipsor$3.36M$10.19M$13.29M
SPRIX Nasal Spray$9.11M$8.68M$11.08M
Royalties And Milestones$2.40M$2.58M$1.52M
Product, Other$4.67M$5.03M-
Product$155.12M$109.42M$93.50M
Otrexup$11.15M--
INDOCIN Products$100.34M$60.56M$31.68M
Product and Service, Other-$-985.00K$9.10M
Commercialization Agreement--$11.26M

Fiscal year ends in Dec 23 | Currency in USD

ASRT Financial Summary


Dec 23Dec 22Dec 21
Revenue$152.07M$156.23M$111.01M
Operating Income$24.94M$57.81M$9.42M
Net Income$-331.94M$109.63M$-1.28M
EBITDA$53.17M$91.21M$39.83M
Basic EPS$-4.67$2.33$-0.03
Diluted EPS$-4.67$2.03$-0.03

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 11, 24 | 6:57 PM
Q2 24Aug 07, 24 | 9:45 PM
Q1 24May 06, 24 | 7:07 PM

Peer Comparison


TickerCompany
ITCIIntra-Cellular Therapies, Inc.
RDYDr. Reddy's Laboratories Limited
ANIPANI Pharmaceuticals, Inc.
AMRXAmneal Pharmaceuticals, Inc.
LFCRLifecore Biomedical, Inc.
ESPREsperion Therapeutics, Inc.
ALVOAlvotech
NBIXNeurocrine Biosciences, Inc.
IRWDIronwood Pharmaceuticals, Inc.
ACRXTalphera, Inc.
DCPHDeciphera Pharmaceuticals, Inc.
AGRXAgile Therapeutics, Inc.
ALKSAlkermes plc
PCRXPacira BioSciences, Inc.
COLLCollegium Pharmaceutical, Inc.
CTLTCatalent, Inc.
EGRXEagle Pharmaceuticals, Inc.
EOLSEvolus, Inc.
AMPHAmphastar Pharmaceuticals, Inc.